Loading...

Thursday, June 25, 2020 Houston

Hope Biosciences Stem Cell Research Foundation to Treat Amyotropic Lateral Sclerosis Patient Autologous Adipose-Derived Mesenchymal Stem Cells for the Treatment of ALS

Hope Biosciences Stem Cell Research Foundation, a non-profit research organization, has received approval from IRB and FDA to treat patient with advanced Amyotrophic Lateral Sclerosis (ALS) with Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs). This patient has banked her stem cells with Hope Biosciences, LLC, which will be used to manufacture the treatment.

Amyotropic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease, often included in a group of conditions classified as motor neuron disease. ALS has a prevalence of approximately 5 in 100,000, with an incidence of 1.7 per 100,000. The pathophysiology of ALS is multifactorial. ALS involves both upper and lower motor neuron degeneration, resulting in spasticity, clumsiness, exaggerated reflexes, functional limitations, and muscle weakness. Neuroinflammation has been indicated as a major component contributing to progression of ALS. Targeting inflammation is a common application of mesenchymal stem cells (MSCs). In many conditions and injuries, inflammation contributes to the chronicity, pain, and degeneration associated with the indication. MSCs have shown promise in studies of other neurodegenerative conditions, including Parkinson’s disease, Alzheimer’s disease, and multiple sclerosis. Combined with our knowledge of the anti-inflammatory and immunomodulatory potential of MSCs, and a superior safety profile, we decided to pursue treatment for an individual with ALS. The study protocol has been approved by both IRB and FDA and will begin in July 2020.

The expanded access study will provide ten monthly intravenous infusions of 200 million HB-adMSCs to an individual patient experiencing rapid decline. Based upon our other studies treating neurodegenerative conditions, we expect to slow the progression of disease for this patient. We would like to develop a larger study, focused on treating several ALS patients, providing them the chance to improve their current condition. If you or a loved one is suffering from ALS and would be interested in learning more about potential future studies, please contact us.

These studies are fully funded by the Hope Biosciences Stem Cell Research Foundation and strictly for humanitarian purposes. Hope Biosciences Stem Cell Research Foundation is administered through the Greater Houston Community Foundation (GHCF). As one of the leading philanthropic grant makers, GHCF is proud to partner with donors to create a meaningful and long-lasting impact in our community. Focused on the community, the core values of HBSCRF include stewardship, transparency and accountability. This pandemic has created a tremendous opportunity to share abilities and resources to contribute to a solution. HBSCRF aims to be completely transparent with its operations and collaborations, providing clear information about all aspects of the studies.

Interested in helping to fund a study? please click here.

Thursday, April 23, 2020 Houston

Hope Biosciences Stem Cell Research Foundation Completes First Treatments for COVID-19 Mesenchymal Stem Cells for Prevention and Treatment

Hope Biosciences Stem Cell Research Foundation successfully completes the first eleven treatments for immune support against COVID-19. This is the first of three FDA-approved clinical trials targeting COVID-19 that the foundation is executing. The first study is providing autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to patients who have already banked their stem cells with Hope Biosciences. Many patients choose to bank their adipose-derived mesenchymal stem cells with Hope Biosciences with the hope of receiving their cells in the future for injury, illness, or ideally, prevention.

HBSCRF celebrated its Grand Opening in March 2020, with the mission of funding translational research in regenerative medicine to develop cures for all. At the time, Coronavirus was becoming an increasing concern in the US. HBSCRF and its board members understood the need of the community and decided to pivot the focus to preventing and treating COVID-19. “It is a privilege and an honor to serve our community during this pandemic. HBSCRF has the unique ability to adapt quickly, developing clinical trials and achieving FDA approval so we can provide stem cells immediately. We wanted to provide options for treatment that would address the full spectrum of needs – prevention through severe illness. These trials are allowing us to help as many people as possible, and we are so grateful for this opportunity,” said Katherine Ruppert, Director of Research at HBSCRF.

The second trial, expected to begin enrolling participants in May, will focus on frontline workers. Included will be doctors, nurses, support staff, etc., who are at a higher risk of exposure. Participants will receive 5 infusions of allogeneic HB-adMSCs with the purpose of providing immune support against COVID-19. The third trial is designed for patients already hospitalized with COVID-19. Patients will receive 4 infusions of allogeneic HB-adMSCs or placebo, in addition to standard care. Primary endpoints for these studies include development of symptoms associated with COVID-19, new requirement for invasive mechanical ventilation, and 28-day mortality. Secondary endpoints will measure regular lab values, as well as inflammatory markers, a key component of the cytokine storm that has been associated with increased progression of COVID-19 infection.

These studies are fully funded by the Hope Biosciences Stem Cell Research Foundation and strictly for humanitarian purposes. Hope Biosciences Stem Cell Research Foundation is administered through the Greater Houston Community Foundation (GHCF). As one of the leading philanthropic grant makers, GHCF is proud to partner with donors to create a meaningful and long-lasting impact in our community. Focused on the community, the core values of HBSCRF include stewardship, transparency and accountability. This pandemic has created a tremendous opportunity to share abilities and resources to contribute to a solution. HBSCRF aims to be completely transparent with its operations and collaborations, providing clear information about all aspects of the studies. Please visit hopebio.org for up-to-date information on our progress.

Thursday, March 5, 2020 Houston

Official launch of Hope Biosciences Stem Cell Research Foundation

Today we announce the official launch of Hope Biosciences Stem Cell Research Foundation, a new non-profit organization to assist translational research in regenerative medicine and to revolutionize the way we treat disease and injury.

The mission of Hope Biosciences Stem Cell Research Foundation (HBSCRF) is to fund translational research in regenerative medicine to develop cures for all. HBSCRF will accomplish this mission through support of research studies and clinical trials focused on advancing the field of regenerative medicine, specifically cell-based therapeutics. Indications for regenerative medicine therapeutics include serious conditions such as neurodegenerative disease, neurological injury, and autoimmune disease. Priority will be assigned to conditions that currently have no effective treatments available, and those that have current therapeutics with a significant side effect burden.

“The Hope Biosciences Stem Cell Research Foundation strives to provide innovative, results-based solutions for patients. Our goal is to be transparent in our efforts and accountable for operating a Foundation based on compassion, integrity, and stewardship. Our top priority is providing cures for patients,” stated founder Donna Chang.

Our Board has been assembled to provide leadership for programs and services, assist in fundraising and advocacy of the organization, and provide unbiased assessment of opportunities.

“HBSCRF is committed to supporting and designing research that focuses on improving the patients’ quality of life. We are exploring new technologies that are disrupting conventional medicine, challenging the way treatments have traditionally been developed and delivered to patients,” says Katherine Ruppert, Director of Research at Hope Biosciences Stem Cell Research Foundation.

Hope Biosciences Stem Cell Research Foundation is administered through the Greater Houston Community Foundation (GHCF). As one of the leading philanthropic grant makers, GHCF is proud to partner with donors to create a meaningful and long-lasting impact in our community.

If you would like to learn more about Hope Biosciences Stem Cell Research Foundation, please visit our website at www.hopebio.org

To make a gift, please click https://ghcf.kimbia.com/hopebiosciences Checks can also be made payable to Hope Biosciences Stem Cell Research Foundation and mailed to:

c/o Greater Houston Community Foundation
515 Post Oak Blvd.
Suite 1000
Houston, TX 77027

Donate Now